PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33708885-0 2021 FEN1 is a prognostic biomarker for ER+ breast cancer and associated with tamoxifen resistance through the ERalpha/cyclin D1/Rb axis. Tamoxifen 73-82 cyclin D1 Homo sapiens 114-126 33839437-12 2021 The role of cyclin D1 as potential parameter of response to tamoxifen was not as pronounced. Tamoxifen 60-69 cyclin D1 Homo sapiens 12-21 33275817-6 2021 We showed that both tamoxifen and ISA-2011B exert their on-target effects on prostate cancer cells by targeting cyclin D1 and PIP5K1alpha/AKT network and the interlinked estrogen signaling. Tamoxifen 20-29 cyclin D1 Homo sapiens 112-121 33708885-9 2021 Importantly, FEN1 over-expression could activate tamoxifen resistance through the ERalpha/cyclin D1/Rb axis. Tamoxifen 49-58 cyclin D1 Homo sapiens 90-102 33708885-10 2021 Conclusions: As a biomarker of tamoxifen effectiveness, FEN1 participates in tamoxifen resistance through ERalpha/cyclin D1/Rb axis. Tamoxifen 31-40 cyclin D1 Homo sapiens 114-126 33708885-10 2021 Conclusions: As a biomarker of tamoxifen effectiveness, FEN1 participates in tamoxifen resistance through ERalpha/cyclin D1/Rb axis. Tamoxifen 77-86 cyclin D1 Homo sapiens 114-126 33519190-0 2021 Paeoniflorin Sensitizes Breast Cancer Cells to Tamoxifen by Downregulating microRNA-15b via the FOXO1/CCND1/beta-Catenin Axis. Tamoxifen 47-56 cyclin D1 Homo sapiens 102-107 33177647-4 2020 Coffee decoction cooperated with tamoxifen to induce cell-cycle arrest and apoptotic cell death, which may have been mediated by decreases in cyclin D1 expression and the activation of p53 tumor suppressor. Tamoxifen 33-42 cyclin D1 Homo sapiens 142-151 33139730-1 2020 Cyclin D1 is one of the most important oncoproteins that drives cancer cell proliferation and associates with tamoxifen resistance in breast cancer. Tamoxifen 110-119 cyclin D1 Homo sapiens 0-9 33139730-2 2020 Here, we identify a lncRNA, DILA1, which interacts with Cyclin D1 and is overexpressed in tamoxifen-resistant breast cancer cells. Tamoxifen 90-99 cyclin D1 Homo sapiens 56-65 33139730-5 2020 High expression of DILA1 is associated with overexpressed Cyclin D1 protein and poor prognosis in breast cancer patients who received tamoxifen treatment. Tamoxifen 134-143 cyclin D1 Homo sapiens 58-67 33139730-6 2020 This study shows the previously unappreciated importance of post-translational dysregulation of Cyclin D1 contributing to tamoxifen resistance in breast cancer. Tamoxifen 122-131 cyclin D1 Homo sapiens 96-105 33139730-7 2020 Moreover, it reveals the novel mechanism of DILA1 in regulating Cyclin D1 protein stability and suggests DILA1 is a specific therapeutic target to downregulate Cyclin D1 protein and reverse tamoxifen resistance in treating breast cancer. Tamoxifen 190-199 cyclin D1 Homo sapiens 64-73 33050377-2 2020 Tamoxifen is the golden therapy for hormonal BC, but resistance of cancer cells to tamoxifen contributes to the recurrence of BC due to many reasons, including high levels of AIB1 and cyclin D1. Tamoxifen 83-92 cyclin D1 Homo sapiens 184-193 31742207-11 2019 Conclusion: Addition of emodin attenuated tamoxifen"s treatment effect via cyclin D1 and pERK up-regulation in ER-positive breast cancer cell lines. Tamoxifen 42-51 cyclin D1 Homo sapiens 75-84 32722075-11 2020 The results suggested that the synergistic cytotoxic effect of LY and TAM is achieved by the induction of apoptosis and cell cycle arrest through cyclin D1, pAKT, caspases, and Bcl-2 signaling pathways. Tamoxifen 70-73 cyclin D1 Homo sapiens 146-155 31975484-5 2020 The combination of these agents also more efficiently reduced major molecular drivers of BC proliferation in the tamoxifen-resistant cells, including c-Myc, cyclin D1 and p-AKT, while up-regulating the cell cycle inhibitor, p27, and inhibiting oncogenic phosphorylation of ER-alpha at Ser167. Tamoxifen 113-122 cyclin D1 Homo sapiens 157-166 27519631-0 2016 Tamoxifen has a proliferative effect in endometrial carcinoma mediated via the GPER/EGFR/ERK/cyclin D1 pathway: A retrospective study and an in vitro study. Tamoxifen 0-9 cyclin D1 Homo sapiens 93-102 28415819-0 2017 Aspirin regulation of c-myc and cyclinD1 proteins to overcome tamoxifen resistance in estrogen receptor-positive breast cancer cells. Tamoxifen 62-71 cyclin D1 Homo sapiens 32-40 28415819-4 2017 Aspirin combined with tamoxifen can down regulate cyclinD1 and block cell cycle in G0/G1 phase. Tamoxifen 22-31 cyclin D1 Homo sapiens 50-58 28415819-5 2017 Besides, tamoxifen alone represses c-myc, progesterone receptor (PR) and cyclinD1 in MCF-7 cell line but not in MCF-7/TAM, while aspirin combined with tamoxifen can inhibit the expression of these proteins in the resistant cell line. Tamoxifen 9-18 cyclin D1 Homo sapiens 73-81 28415819-5 2017 Besides, tamoxifen alone represses c-myc, progesterone receptor (PR) and cyclinD1 in MCF-7 cell line but not in MCF-7/TAM, while aspirin combined with tamoxifen can inhibit the expression of these proteins in the resistant cell line. Tamoxifen 151-160 cyclin D1 Homo sapiens 73-81 28415819-6 2017 When knocking down c-myc in MCF-7/TAM, cells become more sensitive to tamoxifen, cell cycle is blocked as well, indicating that aspirin can regulate c-myc and cyclinD1 proteins to overcome tamoxifen resistance. Tamoxifen 70-79 cyclin D1 Homo sapiens 159-167 28415819-6 2017 When knocking down c-myc in MCF-7/TAM, cells become more sensitive to tamoxifen, cell cycle is blocked as well, indicating that aspirin can regulate c-myc and cyclinD1 proteins to overcome tamoxifen resistance. Tamoxifen 189-198 cyclin D1 Homo sapiens 159-167 30467747-4 2019 In the current study, low concentrations of BPA reduced TAM-induced cytotoxicity of MCF-7 cells, which was proved by the suppression of cell apoptosis, transition of cell cycle from G1 to S phase, and upregulation of cyclin D1 and ERalpha. Tamoxifen 56-59 cyclin D1 Homo sapiens 217-226 24367492-3 2013 CCND1 (cyclin D1) gene amplification is a putative candidate tamoxifen predictive biomarker. Tamoxifen 61-70 cyclin D1 Homo sapiens 0-5 25846733-9 2015 This study suggested that long-term endocrine therapy facilitates leptin and ObRb overexpression in breast cancer cells, which attenuates the inhibitory effect of tamoxifen by activating both the ERK1/2 and STAT3 signaling pathways and upregulating CCND1 gene expression. Tamoxifen 163-172 cyclin D1 Homo sapiens 249-254 24563328-11 2014 Expression levels of CCND1, HER2, AIB1 and NCOR1 were detected as independent predictors of recurrence in this cohort of tamoxifen-treated patients. Tamoxifen 121-130 cyclin D1 Homo sapiens 21-26 24367492-3 2013 CCND1 (cyclin D1) gene amplification is a putative candidate tamoxifen predictive biomarker. Tamoxifen 61-70 cyclin D1 Homo sapiens 7-16 23874806-9 2013 The cell cycle regulator cyclin D1 (CCND1) showed significant up-regulation following treatment with TAM. Tamoxifen 101-104 cyclin D1 Homo sapiens 25-34 23874806-9 2013 The cell cycle regulator cyclin D1 (CCND1) showed significant up-regulation following treatment with TAM. Tamoxifen 101-104 cyclin D1 Homo sapiens 36-41 23755153-6 2014 Tamoxifen treatment significantly altered the hormone receptor expression levels of the tumor, while additionally upregulating Bcl-2 and Cyclin D1. Tamoxifen 0-9 cyclin D1 Homo sapiens 137-146 22422660-7 2012 Combined administration of furanodiene and TAM led to marked increase in growth inhibition, cell cycle arrest and pro-apoptotic activity in ERa-positive cells compared to individual agent, and enhanced the down-regulation of p-cyclin D1, cyclin D1, CDK2, CDK6, p-Rb, Rb and p-p44, and the up-regulation of p27, Bax and Bad, but did not show increased cytotoxicity in ERa-negative MCF-10A non-tumorigenic breast epithelial cells. Tamoxifen 43-46 cyclin D1 Homo sapiens 227-236 22422660-7 2012 Combined administration of furanodiene and TAM led to marked increase in growth inhibition, cell cycle arrest and pro-apoptotic activity in ERa-positive cells compared to individual agent, and enhanced the down-regulation of p-cyclin D1, cyclin D1, CDK2, CDK6, p-Rb, Rb and p-p44, and the up-regulation of p27, Bax and Bad, but did not show increased cytotoxicity in ERa-negative MCF-10A non-tumorigenic breast epithelial cells. Tamoxifen 43-46 cyclin D1 Homo sapiens 238-247 18393977-3 2008 The aim was to investigate gene copy numbers of CCND1 and EMSY and to determine if CCND1 amplification is associated with reduced survival of tamoxifen-treated breast cancer patients. Tamoxifen 142-151 cyclin D1 Homo sapiens 83-88 22475046-2 2012 CCND1 amplification and protein overexpression have also been associated with resistance to treatment with tamoxifen or even to a potentially detrimental effect of tamoxifen. Tamoxifen 107-116 cyclin D1 Homo sapiens 0-5 22475046-2 2012 CCND1 amplification and protein overexpression have also been associated with resistance to treatment with tamoxifen or even to a potentially detrimental effect of tamoxifen. Tamoxifen 164-173 cyclin D1 Homo sapiens 0-5 22475046-9 2012 CONCLUSIONS: In summary, CCND1 amplification and low nuclear expression of cyclin D1 predicted poor clinical outcome in postmenopausal breast cancer patients treated with either anastrozole or tamoxifen. Tamoxifen 193-202 cyclin D1 Homo sapiens 25-30 22475046-9 2012 CONCLUSIONS: In summary, CCND1 amplification and low nuclear expression of cyclin D1 predicted poor clinical outcome in postmenopausal breast cancer patients treated with either anastrozole or tamoxifen. Tamoxifen 193-202 cyclin D1 Homo sapiens 75-84 22266527-13 2012 The low doses of dietary genistein abrogated the inhibitory effect of tamoxifen potentially by acting on the tumor cell proliferation/apoptosis ratio and the messenger RNA (mRNA) expression of cyclin D1 in addition to regulating the mRNA expression of progesterone receptor. Tamoxifen 70-79 cyclin D1 Homo sapiens 193-202 18280643-4 2008 In patients treated with tamoxifen, a trend to significant relation between poor outcome and cyclin D1 mRNA was found. Tamoxifen 25-34 cyclin D1 Homo sapiens 93-102 19636701-0 2010 Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers. Tamoxifen 88-97 cyclin D1 Homo sapiens 20-25 19636701-4 2010 Both CCND1 and EMSY amplifications were associated with a significantly worse outcome in ER-positive patients treated with tamoxifen only, in contrast to nonamplified tumors (P = 8.55 x 10(-4) and P = 8.35 x 10(-5), respectively). Tamoxifen 123-132 cyclin D1 Homo sapiens 5-10 19636701-8 2010 In summary, co-amplification of CCND1 and EMSY identified a poor prognostic subset of ER-positive tamoxifen-treated patients. Tamoxifen 98-107 cyclin D1 Homo sapiens 32-37 20010939-2 2010 Anti-estrogens, such as tamoxifen, antagonise estrogen-induced ERalpha transactivation of cyclin D1, resulting in reduced CDK4/6 activity, p27(Kip1)-mediated inhibition of CDK2 and growth arrest. Tamoxifen 24-33 cyclin D1 Homo sapiens 90-99 19584281-7 2009 In particular, ERbeta was able to translate the effects of SDF-1 on its own expression, as well as enhance activator protein 1 (AP-1) containing genes cyclin D1 and c-Myc in the presence of tamoxifen. Tamoxifen 190-199 cyclin D1 Homo sapiens 151-160 18347178-1 2008 PURPOSE: The objective of our study was to determine the clinical relevance of cyclin D1 expression in hormone receptor-positive breast cancer patients who were treated with tamoxifen-based therapy. Tamoxifen 174-183 cyclin D1 Homo sapiens 79-88 18347178-9 2008 CONCLUSION: Cyclin D1 expression is an independent poor prognostic factor in women with early-stage, hormone receptor-positive breast cancer who received adjuvant tamoxifen-based therapy. Tamoxifen 163-172 cyclin D1 Homo sapiens 12-21 18823530-2 2008 We have previously reported amplification of one such oncogene, namely CCND1, to be correlated with an adverse effect of tamoxifen in premenopausal breast cancer patients. Tamoxifen 121-130 cyclin D1 Homo sapiens 71-76 18347178-0 2008 Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy. Tamoxifen 66-75 cyclin D1 Homo sapiens 0-9 18245487-0 2008 Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3. Tamoxifen 0-9 cyclin D1 Homo sapiens 35-44 18245487-4 2008 In contrast, molecular pathways linking overexpression of cyclin D1 to tamoxifen resistance have not been established. Tamoxifen 71-80 cyclin D1 Homo sapiens 58-67 18245487-5 2008 In the current study, the effect of tamoxifen on the growth of genetically matched high or low cyclin D1-expressing breast cancer cells was characterized and the interactions between cyclin D1, ER, and STAT3 in response to tamoxifen treatment were determined. Tamoxifen 36-45 cyclin D1 Homo sapiens 95-104 18245487-5 2008 In the current study, the effect of tamoxifen on the growth of genetically matched high or low cyclin D1-expressing breast cancer cells was characterized and the interactions between cyclin D1, ER, and STAT3 in response to tamoxifen treatment were determined. Tamoxifen 223-232 cyclin D1 Homo sapiens 183-192 18245487-6 2008 We show that repression of STAT3 by cyclin D1 inhibits cell growth on Matrigel and in tumors in vivo; however, treatment with tamoxifen abolishes cyclin D1-mediated repression of STAT3 and growth suppression. Tamoxifen 126-135 cyclin D1 Homo sapiens 146-155 18245487-7 2008 We show that tamoxifen induces a redistribution of cyclin D1 from STAT3 to the ER, which results in the activation of both STAT3 and the ER. Tamoxifen 13-22 cyclin D1 Homo sapiens 51-60 18245487-8 2008 These results offer a molecular mechanism for the dual effect of cyclin D1 overexpression in breast cancer and support the notion that the level of cyclin D1 expression and activated STAT3 are important markers to predict response to tamoxifen treatment. Tamoxifen 234-243 cyclin D1 Homo sapiens 65-74 18245487-8 2008 These results offer a molecular mechanism for the dual effect of cyclin D1 overexpression in breast cancer and support the notion that the level of cyclin D1 expression and activated STAT3 are important markers to predict response to tamoxifen treatment. Tamoxifen 234-243 cyclin D1 Homo sapiens 148-157 19202962-12 2008 CONCLUSION: The advanced clinical stage, cyclin D1 and Her-2 gene amplifications represent factors, predicting the failure of adjuvant tamoxifen treatment, but their predictive value is much lower in patients receiving adjuvant chemotherapy. Tamoxifen 135-144 cyclin D1 Homo sapiens 41-50 18823530-3 2008 Over-expression of cyclin D1 protein, however, confers tamoxifen resistance but not a tamoxifen-induced adverse effect. Tamoxifen 55-64 cyclin D1 Homo sapiens 19-28 17145896-0 2006 Cyclin D1 is necessary for tamoxifen-induced cell cycle progression in human breast cancer cells. Tamoxifen 27-36 cyclin D1 Homo sapiens 0-9 17593037-9 2007 In this trial, HER-2 and CD1 proved of borderline significance as predictive factors for recurrence on tamoxifen. Tamoxifen 103-112 cyclin D1 Homo sapiens 25-28 17640162-9 2007 The expressions of cyclin D1, estrogen receptor alpha, human epidermal growth factor receptor 2, and insulin-like growth factor I receptor in the TAM group were significantly reduced when TAM was combined with 5FS or 10FS. Tamoxifen 146-149 cyclin D1 Homo sapiens 19-28 17640162-9 2007 The expressions of cyclin D1, estrogen receptor alpha, human epidermal growth factor receptor 2, and insulin-like growth factor I receptor in the TAM group were significantly reduced when TAM was combined with 5FS or 10FS. Tamoxifen 188-191 cyclin D1 Homo sapiens 19-28 17486065-0 2007 Amplification of CCND1 and PAK1 as predictors of recurrence and tamoxifen resistance in postmenopausal breast cancer. Tamoxifen 64-73 cyclin D1 Homo sapiens 17-22 17486065-4 2007 Here, we investigate the prognostic and treatment predictive role of CCND1 and PAK1 gene amplification in postmenopausal breast cancer patients randomized to tamoxifen treatment or no adjuvant treatment. Tamoxifen 158-167 cyclin D1 Homo sapiens 69-74 17145896-3 2006 Here, we investigate the role of cyclin D1, a mediator of estrogen-dependent proliferation, in growth of tamoxifen-resistant cells using a cell culture model of acquired resistance to tamoxifen. Tamoxifen 105-114 cyclin D1 Homo sapiens 33-42 17145896-3 2006 Here, we investigate the role of cyclin D1, a mediator of estrogen-dependent proliferation, in growth of tamoxifen-resistant cells using a cell culture model of acquired resistance to tamoxifen. Tamoxifen 184-193 cyclin D1 Homo sapiens 33-42 17145896-5 2006 Down-regulation of cyclin D1 with small interfering RNA blocked basal cell growth of tamoxifen-resistant cells and induction of cell proliferation by OHT. Tamoxifen 85-94 cyclin D1 Homo sapiens 19-28 17145896-7 2006 These findings indicate that cyclin D1 expression is necessary for proliferation of tamoxifen-resistant cells and for tamoxifen-induced cell cycle progression. Tamoxifen 84-93 cyclin D1 Homo sapiens 29-38 17145896-7 2006 These findings indicate that cyclin D1 expression is necessary for proliferation of tamoxifen-resistant cells and for tamoxifen-induced cell cycle progression. Tamoxifen 118-127 cyclin D1 Homo sapiens 29-38 17145896-8 2006 These results suggest that therapeutic strategies to block cyclin D1 expression or function may inhibit development and growth of tamoxifen-resistant tumors. Tamoxifen 130-139 cyclin D1 Homo sapiens 59-68 15544931-0 2004 Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. Tamoxifen 67-76 cyclin D1 Homo sapiens 0-9 16740736-5 2006 MKP3 overexpression was associated with lower levels of activated extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation in the presence of estrogen but that estrogen deprivation and tamoxifen treatment decreased MKP3 phosphatase activity, leading to an up-regulation of pERK1/2 MAPK, phosphorylated Ser(118)-ER-alpha, and cyclin D1. Tamoxifen 195-204 cyclin D1 Homo sapiens 335-344 15868442-3 2005 Here we investigated the prognostic significance of cyclin D1 among 230 breast cancer patients randomised for tamoxifen, CMF chemotherapy and radiotherapy. Tamoxifen 110-119 cyclin D1 Homo sapiens 52-61 15868442-9 2005 Among oestrogen receptor positive patients, those with moderate cyclin D1 expression significantly did benefit from tamoxifen treatment (RR = 0.42; 95% CI, 0.21-0.82) whereas those with weak or strong expression did not. Tamoxifen 116-125 cyclin D1 Homo sapiens 64-73 15868442-10 2005 Therefore cyclin D1 might be a predictive marker for tamoxifen resistance. Tamoxifen 53-62 cyclin D1 Homo sapiens 10-19 16705121-6 2006 Tamoxifen responsiveness of human MCF-7 breast cancer cells that inducibly expressed constitutively active Pak1 or that transiently overexpressed wild-type Pak1 (Wt-Pak1) or Pak1 that lacked functional nuclear localization signals (Pak1DeltaNLS) was evaluated by analyzing cyclin D1 promoter activation and protein levels as markers for ERalpha activation. Tamoxifen 0-9 cyclin D1 Homo sapiens 273-282 16140974-0 2005 Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification. Tamoxifen 27-36 cyclin D1 Homo sapiens 73-82 16140974-6 2005 Consequently, a highly significant interaction between tamoxifen treatment and CCND1 amplification could be shown regarding both recurrence-free survival (RR, 6.38; 95% CI, 2.29-17.78; P < 0.001) and overall survival (RR, 5.34; 95% CI, 1.84-15.51; P = 0.002), suggesting an agonistic effect of tamoxifen in ER-positive tumors. Tamoxifen 55-64 cyclin D1 Homo sapiens 79-84 16140974-6 2005 Consequently, a highly significant interaction between tamoxifen treatment and CCND1 amplification could be shown regarding both recurrence-free survival (RR, 6.38; 95% CI, 2.29-17.78; P < 0.001) and overall survival (RR, 5.34; 95% CI, 1.84-15.51; P = 0.002), suggesting an agonistic effect of tamoxifen in ER-positive tumors. Tamoxifen 297-306 cyclin D1 Homo sapiens 79-84 16140974-8 2005 In summary, our data implicate that despite a significant correlation to cyclin D1 protein expression, amplification status of the CCND1 gene seems a strong independent predictor of tamoxifen response, and possibly agonism, in premenopausal breast cancer. Tamoxifen 182-191 cyclin D1 Homo sapiens 131-136 15585645-6 2004 CONCLUSIONS: Tamoxifen has been shown to inhibit ERalpha-mediated cyclin D1 transcription, and acquired resistance to tamoxifen is associated with a shift to ERalpha-independent cyclin D1 up-regulation. Tamoxifen 13-22 cyclin D1 Homo sapiens 66-75 15585645-6 2004 CONCLUSIONS: Tamoxifen has been shown to inhibit ERalpha-mediated cyclin D1 transcription, and acquired resistance to tamoxifen is associated with a shift to ERalpha-independent cyclin D1 up-regulation. Tamoxifen 118-127 cyclin D1 Homo sapiens 178-187 15544931-4 2004 In tamoxifen-sensitive breast cancer cells, tamoxifen inhibits, whereas estrogen induces, expression of cyclin D1, a key cell cycle regulatory protein. Tamoxifen 3-12 cyclin D1 Homo sapiens 104-113 15544931-4 2004 In tamoxifen-sensitive breast cancer cells, tamoxifen inhibits, whereas estrogen induces, expression of cyclin D1, a key cell cycle regulatory protein. Tamoxifen 44-53 cyclin D1 Homo sapiens 104-113 15544931-6 2004 Thus, to determine whether cyclin D1 is involved in the growth of tamoxifen-resistant cells, we developed several tamoxifen-resistant variants from MCF-7 cells. Tamoxifen 66-75 cyclin D1 Homo sapiens 27-36 15544931-8 2004 We show here that cyclin D1 expression is maintained at comparable levels in all tamoxifen-resistant variants, whereas pS2, another estrogen-regulated protein, is not. Tamoxifen 81-90 cyclin D1 Homo sapiens 18-27 15544931-11 2004 Thus, changes in cyclin D1 expression upon second-line hormonal therapy may predict hormonal sensitivity of tamoxifen-resistant tumors. Tamoxifen 108-117 cyclin D1 Homo sapiens 17-26 15544931-12 2004 These studies suggest that estrogen receptor mediates cyclin D1 expression and growth of tamoxifen-resistant tumors. Tamoxifen 89-98 cyclin D1 Homo sapiens 54-63 9199341-2 1997 Addition of estradiol relieves the cell cycle block created by tamoxifen treatment, leading to marked activation of cyclin E-cdk2 complexes and phosphorylation of the retinoblastoma protein within 6 h. Cyclin D1 levels increase significantly while the levels of cyclin E, cdk2, and the p21 and p27 cdk inhibitors are relatively constant. Tamoxifen 63-72 cyclin D1 Homo sapiens 202-211 15138474-5 2004 A combination of histological grade plus immunochemical staining for BCL-2, p27 and Cyclin D1, generated a useful prognostic index for tamoxifen-treated patients but not for those treated by surgery alone. Tamoxifen 135-144 cyclin D1 Homo sapiens 84-93 15138475-0 2004 Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Tamoxifen 61-70 cyclin D1 Homo sapiens 0-9 15138475-4 2004 Interestingly in the 55 strongly ERalpha positive samples with moderate or low cyclin D1 levels, patients responded to tamoxifen treatment whereas the 46 patients with highly ERalpha positive and cyclin D1 overexpressing tumours did not show any difference in survival between tamoxifen and no treatment. Tamoxifen 119-128 cyclin D1 Homo sapiens 79-88 15138475-7 2004 Our results suggest that cyclin D1 overexpression predicts for tamoxifen treatment resistance in breast cancer, which is line with recent experimental data using breast cancer cell lines and overexpression systems. Tamoxifen 63-72 cyclin D1 Homo sapiens 25-34 12469160-0 2003 Cyclin D1 expression and patient outcome after tamoxifen therapy in estrogen receptor positive metastatic breast cancer. Tamoxifen 47-56 cyclin D1 Homo sapiens 0-9 12469160-2 2003 We executed this study to evaluate whether therapeutic response to tamoxifen varies with levels of cyclin D1 expression in 66 ER positive breast cancer patients having solitary bone metastasis. Tamoxifen 67-76 cyclin D1 Homo sapiens 99-108 12469160-5 2003 Patients with cyclin D1-expressing tumors showed better response to tamoxifen but the difference was not statistically significant. Tamoxifen 68-77 cyclin D1 Homo sapiens 14-23 10661763-4 1999 In this model, TAM resistance resulted in an increase in the detectable basal levels of cyclin E, GADD 153, p16, BAX, Bcl-XL, and wild-type and mutant p53, an increase in TAM induction of p16, and a decrease in the detectable basal levels of cyclin D1, p21 and p27. Tamoxifen 15-18 cyclin D1 Homo sapiens 242-251 12612058-5 2003 However, cyclin D1 was a key estrogen-induced gene not expressed in response to tamoxifen or raloxifene but constitutively expressed in tamoxifen-resistant cells. Tamoxifen 80-89 cyclin D1 Homo sapiens 9-18 12612058-5 2003 However, cyclin D1 was a key estrogen-induced gene not expressed in response to tamoxifen or raloxifene but constitutively expressed in tamoxifen-resistant cells. Tamoxifen 136-145 cyclin D1 Homo sapiens 9-18 9815758-4 1997 We addressed this question in vitro by testing the ability of ectopic cyclin D1 overexpression to overcome the growth-inhibitory effects of tamoxifen and the pure steroidal antiestrogens, ICI 164384 and ICI 182780, in T-47D and MCF-7 human breast cancer cells. Tamoxifen 140-149 cyclin D1 Homo sapiens 70-79 7585469-3 1995 Estrogen-depletion and treatment with tamoxifen effectively induced a G1-arrest in both cell lines, accompanied by a decrease of the mRNA levels of histone H4, cyclin A, cyclin D1, and c-myc. Tamoxifen 38-47 cyclin D1 Homo sapiens 170-179